Tyrosine kinase inhibitors in oncology - Part 1: Molecular and genetic aspects;Tyrosinkinaseinhibitoren in der tumortherapie - Teil 1: Molekulare und genetische grundlagen

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 21, 2005, Pages 1318-1322

  Grimm, Christian F ^a   Blum, H E ^a   Geissler, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOPOIETIN RECEPTOR; AXITINIB; BCR ABL PROTEIN; BEVACIZUMAB; BIBX 1382BS; BIBX 1383BS; CANERTINIB; CDP 860; CEP 701; CETUXIMAB; CP 724714; CUCURBITACIN GLYCOSIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FLT3 LIGAND; GEFITINIB; HUMAN MONOCLONAL ANTIBODY; IMATINIB; IMC 1C11; INTERLEUKIN 6; JSI 124; LAPATINIB; MATUZUMAB; MIDOSTAURIN; MONOCLONAL ANTIBODY; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PAZOPANIB; PELITINIB; PERTUZUMAB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; STAT3 PROTEIN; STEM CELL FACTOR; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB; ANTINEOPLASTIC AGENT; GROWTH FACTOR RECEPTOR; GROWTH PROMOTOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CARCINOMA; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL TUMOR; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; UTERINE CERVIX CANCER; CHEMISTRY; DIMERIZATION; DRUG ANTAGONISM; ENZYME ACTIVATION; GENETICS; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DIMERIZATION; ENZYME ACTIVATION; GROWTH SUBSTANCES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 20444451300     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-868727     Document Type: Review

References (17)

1. Bjorge JD, Jakymiw A, Fujita DJ. Selected glimpses into the activation and function of Src kinase. Oncogene 2000; 19: 5620-5635
2. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-65
3. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993; 366: 643-654
4. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657
5. Druker BJ et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566
6. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9: 2-10
7. Gibbs JB. Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest 2000; 105: 9-13
8. Hayes AJ, Li LY, Lippman ME. Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment. Bmj 1999; 318: 853-856
9. Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
10. Irby RB et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999; 21: 187-190
11. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49-139
12. Schwarte GK et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002; 20: 2157-2170
13. Sebti SM, Der CJ. Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 2003; 3: 945-951
14. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7: 228-234
15. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501
16. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4: 216-225
17. Zwerner JP, May WA. Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines. Oncogene 2002; 21: 3847-3854